Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

CNBC

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

EconomyDaily Composite
ShareXFacebook

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

C

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Advertisement

Related Economy Stories

Samsung’s AI Bonuses Divide Workers
Bloomberg Markets

Samsung’s AI Bonuses Divide Workers

Samsung has narrowly averted a strike by promising some employees hefty bonuses — dividends from the windfall it’s seen from the AI boom. But that’s stoking unhappiness among other workers who don’t stand to reap equal benefits. (Source: Bloomberg)

Read more →
Advertisement